Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Eisai, Eurofarma Laboratorios deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Eurofarma Laboratorios S.A., Sao Paulo, Brazil Business: Cancer Eisais Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize …

    Published on 10/10/2016
  • Eli Lilly, Cerecor deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Business: Neurology Eli Lilly granted Cerecor exclusive, worldwide rights to develop and commercialize CERC-611 (formerly …

    Published on 10/10/2016
  • EngMab, Celgene deal

    EngMab AG, Pfaeffikon, Switzerland Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Celgene acquired EngMab for $600 million. Celgene said the acquisition will help it pursue tumor necrosis factor receptor …

    Published on 10/10/2016
  • Exosome Diagnostics, Amgen deal

    Exosome Diagnostics Inc., Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Diagnostic Amgen and Exosome will use Exosomes liquid biopsy diagnostics technology to evaluate using a liquid biopsy …

    Published on 10/10/2016
  • Hanmi Pharmaceutical, Boehringer Ingelheim deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Boehringer returned rights to olmutinib (HM61713) to Hanmi, terminating the partners 2015 …

    Published on 10/10/2016
  • Molecular Partners, J&J deal

    Molecular Partners AG (SIX:MOLN), Schlieren, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pulmonary Molecular Partners said it regained rights to a pulmonary disease candidate from the Janssen…

    Published on 10/10/2016
  • Nuevolution, Amgen deal

    Nuevolution AB (SSE:NUE), Copenhagen, Denmark Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Neurology, Cancer, High throughput screening Nuevolution will use its Chemetics platform to discover small …

    Published on 10/10/2016
  • NuMedii deal

    NuMedii Inc., Palo Alto, Calif. Business: Bioinformatics NuMedii partnered with an undisclosed pharmaceutical company to identify new indications for undisclosed compounds from the partner using NuMediis predictive Big …

    Published on 10/10/2016
  • Rutgers University, Biohaven deal

    Rutgers University, New Brunswick, N.J. Biohaven Pharmaceutical Holding Co. Ltd., Tortola, Virgin Islands Business: Cancer The university granted Biohaven development and commercialization rights to undisclosed …

    Published on 10/10/2016
  • Summit Therapeutics, Sarepta Therapeutics deal

    Summit Therapeutics plc (LSE:SUMM;NASDAQ:SMMT), Abingdon, U.K. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Musculoskeletal Summit granted Sarepta exclusive commercialization rights in Europe, …

    Published on 10/10/2016
  • Verastem, Merck, Cancer Research UK deal

    Verastem Inc. (NASDAQ:VSTM), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Cancer Research UK, London, U.K. Business: Cancer The companies partnered to conduct an open-label, dose-escalation, U.K. Phase…

    Published on 10/10/2016
  • Vivus, Mist Pharmaceuticals deal

    Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Mist Pharmaceuticals LLC, Cranford, N.J. Business: Genitourinary Vivus granted Mists Metuchen Pharmaceuticals LLC affiliate exclusive rights to commercialize erectile …

    Published on 10/10/2016
  • 4SC, Immunic deal

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Immunic AG, Martinsried, Germany Business: Autoimmune Immunic acquired 4SCs immunology portfolio, including preclinical programs IMU-366 and IMU-838. 4SC will receive an …

    Published on 10/3/2016
  • Abide Therapeutics, Celgene deal

    Abide Therapeutics Inc., San Diego, Calif. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Neurology Celgene exercised an option from a 2014 deal and will obtain worldwide rights outside the U.S. to Abides ABX-1431.…

    Published on 10/3/2016
  • Arrowhead, Amgen deal

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Pasadena, Calif. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cardiovascular Arrowhead granted Amgen exclusive, worldwide rights to the ARC-LPA cardiovascular …

    Published on 10/3/2016
  • Ben-Gurion University, Hadassah Medical Organization, BioLineRx deal

    Ben-Gurion University of the Negev, Beer-Shiva, Israel Hadassah Medical Organization, Jerusalem, Israel BioLineRx Ltd. (Tel Aviv:BLRX;NASDAQ:BLRX), Jerusalem, Israel Business: Hepatic The organizations Hadasit Medical …

    Published on 10/3/2016
  • bluebird bio, Medigene deal

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Medigene AG (Xetra:MDG1), Martinsried, Germany Business: Cancer Medigene and bluebird partnered to develop and commercialize T cell receptor (TCR) immunotherapies …

    Published on 10/3/2016
  • Catabasis Pharmaceuticals, Sarepta Therapeutics deal

    Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Musculoskeletal The companies partnered to conduct mouse model research to evaluate …

    Published on 10/3/2016
  • Coherus BioSciences, Shire deal

    Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Autoimmune, Biosimilars Coherus said Shire terminated a 2013 deal and returned rights to CHS-0214, …

    Published on 10/3/2016
  • CRT Pioneer Fund, ProNAi deal

    Cancer Research Technology Pioneer Fund, London, U.K. ProNAi Therapeutics Inc. (NASDAQ:DNAI), Vancouver, B.C. Business: Cancer The fund granted ProNAi exclusive, worldwide rights to develop and commercialize cancer …

    Published on 10/3/2016
  • Evotec, C4X Discovery deal

    Evotec AG (Xetra:EVT), Hamburg, Germany C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K. Business: Autoimmune, Cancer The companies partnered to develop small molecule candidates against undisclosed targets, with…

    Published on 10/3/2016
  • Hanmi Pharmaceutical, Genentech, Roche deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Hanmi granted Roches Genentech unit …

    Published on 10/3/2016
  • Intrexon, CRS Bio deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. CRS Bio Inc., Germantown, Md. Business: Drug delivery, Inflammation Intrexon granted newco CRS Bio access to Intrexons ActoBiotics technology to deliver antibodies to treat …

    Published on 10/3/2016
  • Intrexon, Genten deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. Genten Therapeutics Inc., Germantown, Md. Business: Autoimmune, Drug delivery Intrexon granted newco Genten exclusive access to Intrexons ActoBiotics technology to deliver …

    Published on 10/3/2016
  • J&J, Tracon deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Tracon Pharmaceuticals Inc. (NASDAQ:TCON), San Diego, Calif. Business: Cancer Johnson & Johnsons Janssen Pharmaceutica N.V. unit granted Tracon exclusive, worldwide …

    Published on 10/3/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993